Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Celldex Therapeutics (CLDX) reported a Q4 loss of $0.71 per share, which was better than the Zacks Consensus Estimate of a $0.75 loss. However, this is a larger loss compared to $0.57 per share a year ago.
February 27, 2025 | 11:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Celldex Therapeutics reported a Q4 loss of $0.71 per share, better than expected but worse than last year's $0.57 loss. This mixed result may lead to short-term volatility in the stock price.
The earnings report shows a better-than-expected loss, which is positive, but the increase in loss compared to last year is negative. This mixed result could lead to short-term volatility in the stock price as investors digest the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100